Generic Name:
Cemiplimab
Project Status:
Complete
Therapeutic Area:
Advanced Cutaneous Squamous Cell Carcinoma (CSCC)
Manufacturer:
Sanofi Genzyme
Brand Name:
Libtayo
Project Line:
Reimbursement Review
Project Number:
PC0187-000
NOC Date:
Details
Strength:
50mg/mL
Tumour Type:
Skin & Melanoma
Indications:
Cutaneous Squamous Cell Carcinoma
Funding Request:
For the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
Review Status:
Complete
Sponsor:
Sanofi Genzyme
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Funding Request:
For the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
pERC Meeting:
Final Recommendation Issued: